- Trials with a EudraCT protocol (8)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
8 result(s) found for: Aneuploidy.
Displaying page 1 of 1.
EudraCT Number: 2011-002425-21 | Sponsor Protocol Number: 11054 | Start Date*: 2012-02-10 |
Sponsor Name:University of Nottingham | ||
Full Title: Efficacy of Dehydroepiandrosterone to overcome the effect of ovarian aging | ||
Medical condition: Women having low ovarian reserve undergoing IVF/ICSI treatment | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2018-003156-20 | Sponsor Protocol Number: HRT_NC-FET | Start Date*: 2019-03-15 |
Sponsor Name:CRG UZ Brussel | ||
Full Title: Natural cycle versus hormone replacement therapy cycle for a frozen-thawed embryo transfer in PGT patients: a randomised trial. | ||
Medical condition: Female infertility | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: BE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2017-000189-31 | Sponsor Protocol Number: PRI04/2016 | Start Date*: 2017-05-12 |
Sponsor Name:Pannon Reprodukciós Intézet B.1.2 | ||
Full Title: Optimization and Safety Testing of Hormone Normalization Therapy in Advanced Maternal Age Infertile Women | ||
Medical condition: The therapy is intended to treat infertility that is caused by declining egg quality that occurs with advanced maternal age. The purpose of this pilot trial is to optimize the therapeutic protocol.... | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: HU (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2022-003792-41 | Sponsor Protocol Number: DAROTAXEL | Start Date*: 2023-05-26 |
Sponsor Name:Erasmus MC | ||
Full Title: A randomized phase II trial of docetaxel or cabazitaxel with or without darolutamide in men with metastatic castration-resistant prostate cancer. | ||
Medical condition: metastatic castration-resistant prostate cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male | |
Trial protocol: NL (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2022-001045-21 | Sponsor Protocol Number: FSD-MIC-2022-03 | Start Date*: 2023-04-10 |
Sponsor Name:FUNDACION SANTIAGO DEXEUS FONT | ||
Full Title: A Phase III randomized controlled trial comparing the efficacy, safety and tolerability of two formulations of vaginal micronized progesterone. | ||
Medical condition: Infertility | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2015-004444-19 | Sponsor Protocol Number: CRIT124D2201 | Start Date*: 2016-04-05 | |||||||||||
Sponsor Name:Novartis Pharmaceutical corporation | |||||||||||||
Full Title: An open-label, behavioral-treatment-controlled evaluation of the effects of extended release methylphenidate (Ritalin® LA) on the frequency of cytogenetic abnormalities in children 6 - 12 years of ... | |||||||||||||
Medical condition: To determine whether the administration of extended-release methylphenidate in treatment-naïve children with ADHD affects the frequency of chromosomal abnormalities. | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-019755-21 | Sponsor Protocol Number: 04-21 | Start Date*: 2011-12-22 | |||||||||||
Sponsor Name:Onconova Therapeutics Inc. | |||||||||||||
Full Title: A Phase III, Multi-Center, Randomized, Controlled Study to Assess the Efficacy and Safety of ON 01910.Na Administered as a 72-Hour Continuous Intravenous Infusion Every Other Week in Myelodysplasti... | |||||||||||||
Medical condition: Myelodysplastic syndrome with excess blasts | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) ES (Ongoing) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-001124-19 | Sponsor Protocol Number: 04-24 | Start Date*: 2013-09-25 | |||||||||||
Sponsor Name:Onconova Therapeutics, Inc. | |||||||||||||
Full Title: Phase IIIB, Open-label, Multi-Center Study of the Efficacy and Safety of rigosertib Administered as 72-hour Continuous Intravenous Infusions in Patients with Myelodysplastic Syndrome with Excess Bl... | |||||||||||||
Medical condition: Myelodysplastic Syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) IT (Completed) SE (Completed) DK (Completed) ES (Completed) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
